Roadmap for launching the regenerative medicine business in 3 stages
First written in FY2017-Q1. 22 of 26 entries say "Restated". Latest entry: FY2026-H1.
0 other companies' latest entry also says "Restated".
- FY2026-H1RestatedAnnual report
「The Group aims to achieve sustainable growth by making the research support business, its short- to medium-term earnings base, and the medical business, its medium- to long-term growth driver, the two pillars of its business.」
The company has reaffirmed its 2-track business model, with the research support business as the short- to medium-term earnings base and the medical business as the medium- to long-term growth driver. - FY2025-H1RestatedAnnual report
「By combining the research support business, its short- to medium-term earnings pillar, with the medical business, its medium- to long-term growth business, we aim to achieve sustainable growth from the short to medium to long term.」
The company has reaffirmed its 2-track growth model, with the research support business as the short- to medium-term source of earnings and the medical business as the medium- to long-term growth business. - FY2024-Q3RestatedAnnual report
「By combining the research support business, its short- to medium-term earnings pillar, with the medical business, its medium- to long-term growth business, we aim to achieve continuous growth from the short to medium to long term.」
The company has reaffirmed its 2-track growth model, with the research support business as the short- to medium-term source of earnings and the medical business as the medium- to long-term growth business. - FY2024-Q2RestatedAnnual report
「By combining the research support business, its short- to medium-term earnings pillar, with the medical business, its medium- to long-term growth business, we aim to achieve continuous growth from the short to medium to long term.」
The company has reaffirmed its 2-track growth model, with the research support business as the short- to medium-term source of earnings and the medical business as the medium- to long-term growth business. - FY2024-Q1RestatedAnnual report
「By combining the research support business, its short- to medium-term earnings pillar, with the medical business, its medium- to long-term growth business, we aim to achieve continuous growth from the short to medium to long term.」
The company has reaffirmed its 2-track growth model, with the research support business as the short- to medium-term source of earnings and the medical business as the medium- to long-term growth business. - FY2023-Q3RestatedAnnual report
「By combining the research support business, its short- to medium-term earnings pillar, with the medical business, its medium- to long-term growth business, we aim to achieve continuous growth from the short to medium to long term.」
The company has reaffirmed its 2-track growth model, with the research support business as the short- to medium-term source of earnings and the medical business as the medium- to long-term growth business. - FY2023-Q2RestatedAnnual report
「By combining the research support business, its short- to medium-term earnings pillar, with the medical business, its medium- to long-term growth business, we aim to achieve continuous growth from the short to medium to long term.」
The company has reaffirmed its 2-track growth model, with the research support business as the short- to medium-term source of earnings and the medical business as the medium- to long-term growth business. - FY2023-Q1RestatedAnnual report
「By combining the research support business, its short- to medium-term earnings pillar, with the medical business, its medium- to long-term growth business, we aim to achieve sustainable growth from the short to medium to long term.」
The company has reaffirmed its 2-track growth model, with the research support business as the short- to medium-term source of earnings and the medical business as the medium- to long-term growth business. - FY2022-Q3RestatedAnnual report
「By combining the research support business, its short- to medium-term earnings pillar, with the medical business, its medium- to long-term growth business, we aim to achieve sustainable growth from the short to medium to long term.」
The company has reaffirmed its 2-track growth model, with the research support business as the short- to medium-term source of earnings and the medical business as the medium- to long-term growth business. - FY2022-Q1RestatedAnnual report
「By combining the research support business, its short- to medium-term earnings pillar, with the medical business, its medium- to long-term growth business, we aim to achieve sustainable growth from the short to medium to long term.」
The company has reaffirmed its 2-track growth model, with the research support business as the short- to medium-term source of earnings and the medical business as the medium- to long-term growth business. - FY2021RestatedAnnual report
「By combining the research support business, its short- to medium-term earnings pillar, with the medical business, its medium- to long-term growth business, we aim to achieve continuous growth from the short to medium to long term.」
The company has reaffirmed a continuous-growth model combining the research support business and the medical business. - FY2021-Q3RestatedAnnual report
「By combining the research support business, its short- to medium-term earnings pillar, with the medical business, its medium- to long-term growth business, we aim to achieve sustainable growth from the short to medium to long term.」
The company has reaffirmed its 2-track growth model, with the research support business as the short- to medium-term source of earnings and the medical business as the medium- to long-term growth business. - FY2021-Q2RestatedAnnual report
「By combining the research support business, its short- to medium-term earnings pillar, with the medical business, its medium- to long-term growth business, we aim to achieve sustainable growth from the short to medium to long term.」
The company has reaffirmed its 2-track growth model, with the research support business as the short- to medium-term source of earnings and the medical business as the medium- to long-term growth business. - FY2021-Q1RestatedAnnual report
「By combining the research support business, its short- to medium-term earnings pillar, with the medical business, its medium- to long-term growth business, we aim to achieve sustainable growth from the short to medium to long term.」
The company has reaffirmed its 2-track business model, with the research support business as the short- to medium-term earnings pillar and the medical business as the medium- to long-term growth business. - FY2020RestatedAnnual report
「The company positions the research support business as its short- to medium-term earnings pillar and the medical business as its medium- to long-term growth business, and aims to achieve sustainable growth from the short to medium to long term by combining the two.」
The company has reaffirmed its 2-track growth model, with the research support business as the short- to medium-term pillar and the medical business as the medium- to long-term pillar. - FY2020-Q3RestatedAnnual report
「By combining the research support business, its short- to medium-term earnings pillar, with the medical business, its medium- to long-term growth business, we aim to achieve continuous growth from the short to medium to long term.」
The company has reaffirmed its 2-track business model, with the research support business as the short- to medium-term earnings pillar and the medical business as the medium- to long-term growth business. - FY2020-Q2RestatedAnnual report
「By combining the research support business, its short- to medium-term earnings pillar, with the medical business, its medium- to long-term growth business, we aim to achieve continuous growth from the short to medium to long term.」
The company has reaffirmed its 2-track business model, with the research support business as the short- to medium-term earnings pillar and the medical business as the medium- to long-term growth business. - FY2020-Q1RestatedAnnual report
「By combining the research support business, its short- to medium-term earnings pillar, with the medical business, its medium- to long-term growth business, we aim to achieve continuous growth from the short to medium to long term.」
The company has reaffirmed its 2-track business model, with the research support business as the short- to medium-term source of earnings and the medical business as the medium- to long-term growth business. - FY2019-Q3RestatedAnnual report
「Against this business backdrop, the Group is developing its research support business, which provides research reagents and drug discovery support services related to iPS cells, as a short- to medium-term business pillar. As a medium- to long-term growth strategy, it is actively investing in the medical business, which is expected to address a huge market, with the aim of becoming a market leader in this field.」
The company has reaffirmed its 2-business structure, developing the research support business as the short- to medium-term pillar and the medical business as the medium- to long-term growth strategy, with the aim of becoming a market leader. - FY2019-Q2RestatedAnnual report
「Against this business backdrop, the Group is developing its research support business, which provides research reagents and drug discovery support services related to iPS cells, as a short- to medium-term business pillar. As a medium- to long-term growth strategy, it is actively investing in the medical business, which is expected to address a huge market, with the aim of becoming a market leader in this field.」
The company has reaffirmed its 2-business structure, with the research support business as the short- to medium-term pillar and the medical business as the medium- to long-term growth strategy. - FY2019-Q1RestatedAnnual report
「Against this business backdrop, the Group is developing its research support business, which provides research reagents and drug discovery support services related to iPS cells, as a short- to medium-term business pillar. As a medium- to long-term growth strategy, it is actively investing in the medical business, which is expected to address a huge market, with the aim of becoming a market leader in this field.」
The company has reaffirmed its 2-business structure, organizing its previous stepwise commercialization concept around the research support business as the short- to medium-term pillar and the medical business as the medium- to long-term growth strategy. - FY2018ReframedAnnual report
「The Group places iPS cells at the core of its business and operates in 2 business areas: the research support business and the medical business. It aims to become a market leader in this field by developing the research support business as a short- to medium-term business pillar and expanding the medical business as a medium- to long-term growth driver.」
The company has organized its previous stepwise commercialization concept into a 2-business structure, with the research support business as the short- to medium-term pillar and the medical business as the medium- to long-term growth driver. - FY2017RestatedAnnual report
「The Group classifies its iPS cell business into 3 areas: research reagents, drug discovery support, and regenerative medicine, and is developing these businesses in stages in line with technological progress and market development.」
The company has reaffirmed its roadmap for developing the business in 3 stages: research reagents, drug discovery support, and regenerative medicine. - FY2017-Q3AdvancedAnnual report
「Regarding “cell-based pharmaceuticals using somatic stem cells,” the company continues to promote technology partnerships through investments by the joint venture fund Cell Innovation Partners, L.P., established with Shinsei Corporate Investment Co., Ltd. During the nine-month period under review, following the first investment in Elastagen, it invested €1 million as its second investment in Belgium-based Promethera, which is developing allogeneic cell-based pharmaceuticals for liver diseases.」
For somatic stem cell pharmaceuticals under the 3-stage roadmap, the company made a €1 million investment in Promethera as its second investment. - FY2017-Q2AdvancedAnnual report
「We are already in discussions with relevant parties, including government agencies, and have begun developing reagents that can be used for clinical applications.」
For the first stage of the 3-stage roadmap, the company explicitly stated that it had begun developing clinical-use reagents. For the second stage, it stated that it had reached the point of being able to pursue a US patent for its hematopoietic stem cell expansion technology. - FY2017-Q1First statedAnnual report
「The roadmap consists of 3 steps: “culture media and reagent products for regenerative medicine,” “cell-based pharmaceuticals using somatic stem cells,” and “cell-based pharmaceuticals using iPS cells.”」
The company plans to commercialize its businesses in the following order: regenerative medicine products, somatic stem cell pharmaceuticals, and iPS cell pharmaceuticals.